BioSpace News Archive

Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 626,000 shares of common stock to 15 newly hired employees.

BioAtla, Inc. announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin and CAB-CTLA-4.

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights.

BioCryst Pharmaceuticals, Inc. announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients.

“Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028" Report Highlights.

Global Alzheimer’s Disease Drug Biomarkers Insight 2028 Report Highlights.

Global Bcr-Abl Inhibitor Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights.

Within these protective micro-environments, stem cells can achieve optimal growth in large-scale bioreactors, and can be differentiated into ready-to-transplant 3D microtissues.

Aadi Bioscience, Inc., a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced the presentation of a poster at the Annual Meeting of the American Association for Cancer Research, being held April 8-13, 2022 in New Orleans, LA.

Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced the results of the prespecified final progression-free survival analysis and the interim overall survival analysis of the JUPITER-02 study, a pivotal Phase 3 trial in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.